{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-045573","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.700341+00:00","generated_at":"2026-06-17T01:46:22.600105+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Eloxx receives Nasdaq delisting notice for failing to maintain $35M market value","bullets":["Received delisting notice on April 11, 2023, for non-compliance with Nasdaq's $35M minimum market value requirement.","Company failed to regain compliance during the 180-day grace period that ended April 10, 2023.","Trading will be suspended on April 20, 2023, unless company requests a hearing by April 18, 2023.","Company intends to appeal; a hearing request will stay the suspension pending Panel decision.","There is no assurance the appeal will succeed or that continued listing will be granted."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-045573","json":"https://secwatch.observer/filing/0001104659-23-045573.json","markdown":"https://secwatch.observer/filing/0001104659-23-045573.md","text":"https://secwatch.observer/filing/0001104659-23-045573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923045573/0001104659-23-045573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923045573/tm2312848d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:46:22.600105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b19baf74133abe18dc1383196fb9f9258e6924d0","claim":"Eloxx Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"April 11, 2023, Eloxx Pharmaceuticals, Inc. (the “ Company ”) received a determination letter (the “ Letter ”) from the staff (the “ Staff ”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that the Company has not regained compliance with Listing Rule 5550(b)(2) (the “ Minimum Market Value Requirement ”), requiring the Company to maintain a Market Value of Listed Securities of a minimum of $35 million, during the 180-day grace period previously granted to the Company. As previously disclosed, the Company was initially notified by the Staff on Octob","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923045573/0001104659-23-045573-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}